Thermo Fisher Scientific Inc.
(TMO) announced that it has acquired Proxeon A/S, an innovative supplier of products for proteomics analysis. Financial terms of the transaction have not been disclosed.
Thermo Fisher plans to integrate Proxeon into its Analytical Technologies Segment. The company does not expect the acquisition to have a material impact on its fiscal 2010 results.
Proxeon A/S provides a simplified proteomics workflow, including nanoflow liquid chromatography systems, columns, ion sources and bioinformatics software. This allows a robust high-sensitivity liquid chromatography/mass spectrometry (LC/MS) analysis in complex proteomics applications. Proxeon generated sales of roughly $10 million in fiscal 2009.
Proxeon’s nanoflow liquid chromatography system, EASY-nLC, is simple and easy to use. The system supports an intuitive graphical user interface and has a remote diagnostics capability. In addition, the compact system footprint allows researchers to improve productivity without comprising performance. EASY-nLC system also identifies more proteins than conventional methods, without the increased complexity of added valves and pumps.
The unique features of EASY-nLC nanoflow liquid chromatography system make it a preferred choice for researchers in a number of the world’s leading proteomic centers. The Proxeon acquisition will help Thermo Fisher to meet the increasing demand for LC/MS in proteomics applications. This in turn will cater to the company’s top-line growth.
Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. in November 2006. Thermo Fisher Scientific serves customers through two principal brands, Thermo Scientific and Fisher Scientific.
Thermo Fisher offers a wide range of products and technology to its customers. This differentiates the company from its peers, giving it a competitive edge.
Presently, we have a ‘Neutral’ recommendation on Thermo Fisher Scientific Inc.

Read the full analyst report on “TMO”
Zacks Investment Research